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Aims Studies have shown that erythrocyte membranes are present within necrotic cores in atherosclerotic plaques, and
that circulating erythrocytes in patients with acute coronary syndrome (ACS) have increased total cholesterol
content (CEM). Interleukin-8 (IL-8) binds to erythrocytes and during intraplaque haemorrhage it is released into
the plaque and thus may contribute to inﬂammatory cascade and atherosclerotic plaque instability. The present
study was undertaken to test the hypothesis that erythrocyte membrane IL-8 is elevated in patients with ACS
compared with those with chronic stable angina (CSA).
Methods
and results
Consecutive patients who presented with CSA (n ¼ 120, 92 men, 62+9 years), ACS (n ¼ 118, 90 men, 62+10
years) or with chest pain who had normal coronary arteries (n ¼ 36, 26 men, 60+7 years), were studied prospec-
tively. IL-8 concentrations in erythrocyte membranes (rIL-8) and in plasma (pIL-8), C-reactive protein (CRP) and
CEM were measured. rIL-8 levels [mean+1 SD (standard deviation)] were higher in ACS (102.9+70.1 pg/mL)
compared with CSA (44.7+22.8 pg/mL) (P , 0.001). No difference in pIL-8 levels between the two coronary
artery disease groups was observed (P ¼ 0.280). Serum CRP levels were correlated with rIL-8 levels (r ¼ 0.294,
P , 0.001); no association was found between CRP and pIL-8 levels (r ¼ 0.025, P ¼ 0.706). Further, rIL-8 had an
independent association with ACS, when CRP and CEM were taken into consideration.
Conclusion This study shows for the ﬁrst time that rIL-8 content was signiﬁcantly higher in ACS, compared with CSA. These
ﬁndings endorse results from our previous studies suggesting that erythrocytes may play an important role in the
development of unstable atherosclerotic plaque.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Erythrocyte membranes † Interleukin-8 † Cholesterol content † Acute coronary syndrome † Chronic stable
angina
Introduction
It has been suggested that erythrocytes could play an active role
in the development of atherosclerotic plaque and in plaque
instability.
1,2 Studies have shown that the necrotic lipid core of
atherosclerotic plaques contains erythrocyte membranes
3,4 and
that total cholesterol levels in the membrane of circulating
erythrocytes (CEM) was increased in patients with acute coronary
syndrome (ACS) compared with patients with chronic stable
angina (CSA).
5
It has been proposed that red blood cells (RBC) rich in choles-
terol may contribute to atherosclerotic plaque expansion leading
to its instability.
1,6 It is also possible that RBC membranes released
within the lipid core during intraplaque haemorrhage, which
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 contain inﬂammatory mediators, such as interleukin-8 (IL-8) may
contribute to plaque growth and instability.
2,4,7–12
The present study was undertaken to investigate whether
patients with ACS have higher erythrocyte IL-8 (rIL-8) concen-
trations compared with patients with CSA.
Methods
Patients population
From November 2006 to September 2007, 312 consecutive patients
who were admitted to our institution for the assessment of their
coronary artery status were recruited prospectively. From those, 20
who did not meet the inclusion criteria (described later), ﬁve who
refused to give their informed consent and 13 in whom data collection
was not complete were excluded from further analysis. The remaining
274 patients represented the study population. Of those, 120 had
CSA, and 118 ACS, 58 (49%) with ST-segment elevation myocardial
infarction (STEMI), 32 (27%) with non-STEMI (NSTEMI) and 28
(24%) with unstable angina (UA). In addition, 36 patients with chest
pain and angiographically normal coronary arteries (NCA) were also
included in the study.
CSA was deﬁned as typical exertional chest pain, relieved by rest
and/or nitrates, without a change in frequency or severity for 3
months prior to study entry, and one of the following: a positive
response (.1 mm ST-segment depression) on the exercise stress
test; reversible or ﬁxed myocardial perfusion defect(s) during myocar-
dial perfusion scintigraphy; segmental wall motion abnormalities at rest
or during stress echocardiography.
13
Myocardial infarction (MI) was diagnosed in the presence of pro-
longed (.20 min) chest pain, with ST-segment changes suggestive of
myocardial ischaemia or necrosis on the standard 12-lead electrocar-
diogram (ECG) associated with increased serum markers of myocardial
necrosis measured on at least two occasions during the ﬁrst 24 h after
the index event (increase above the 99th percentile of the upper refer-
ence limit of creatine kinase-myocardial fraction and troponin-T).
14
Only patients with spontaneous MI (type 1) were recruited. Patients
presented with MI secondary to ischaemia due to increased oxygen
demand or decreased supply (type 2), after cardiac arrest with success-
ful resuscitation and ﬁndings consistent with myocardial ischaemia
(type 3), MI associated with percutaneous coronary intervention
within the ﬁrst 48 h after the procedure (type 4a) or stent thrombosis,
as documented by coronary angiography (type 4b), or MI associated
with coronary artery bypass grafting within the ﬁrst 72 h after the
procedure (type 5)
14 were not included in the study.
MI patients were considered to have STEMI when an elevation of
the ST-segment  0.2 mV was detected in V1 through V3 and/or an
elevation  0.1 mV was found in two or more contiguous ECG
leads.
15 NSTEMI was diagnosed in the presence of new horizontal
or down-sloping ST-segment depression ( 0.05 mV) and/or T-wave
inversion ( 0.1 mV) in two or more contiguous leads.
16 UA was
deﬁned as anginal pain at rest fulﬁlling Braunwald’s IIIb criteria with
transient signiﬁcant ischaemic ST-segment or T-wave changes, or
both, without biochemical evidence for myocardial damage.
17
Patients with unstable coronary artery disease (CAD) (STEMI,
NSTEMI, UA) who underwent urgent cardiac catheterization were
not included in the study, since the acute event may have inﬂuenced
laboratory measurements.
NCA patients group comprised individuals with CAD risk factors
who presented with chest pain and were found to have NCA on
coronary angiography.
Patients with a history of excessive alcohol intake, haematological,
renal, liver, or thyroid diseases, or malignancies were excluded.
Furthermore, patients with infectious or autoimmune diseases, familial
hyperlipidaemia, and those who underwent surgical procedures in the
preceding 3 months were excluded from the study. None of the
patients were receiving anti-inﬂammatory drugs or hormone replace-
ment therapy. Patients with abnormal RBC counts (,4.7 and
.5.9   10
6 per mL for men and ,4.2 and .5.4   10
6 per mL for
women) and/or abnormal haemoglobin levels (,13 and .18 g/dL
for men and ,12 and .16 g/dL for women) were also excluded.
The study was approved by the Local Research Ethics Committee,
and all patients gave written informed consent prior to study entry.
Angiographic analysis
Coronary arteriography was performed using the Judkins technique;
images of the coronary artery tree were obtained on routine, standar-
dized projections with the digital GE ADVANTX LCþ System
(General Electric Medical Systems, S.C.S., Buc, France). Coronary
arteriography was performed within 8–23 days (median 14) from
the acute ischaemic episode in patients with ACS and at least 3
months after an acute episode in patients with CSA. Patients with
chest pain and NCA were studied within 2 weeks from the time of
their referral for coronary arteriography. Two experienced cardiolo-
gists who had no knowledge of the patients’ clinical characteristics
and biochemical results visually reviewed all angiographic images to
assess the extent and severity of CAD using an automated quantitative
coronary artery stenosis assessment process (GE Centricity Cardiol-
ogy CA 1000 Cardiac Review 1.0, General Electric Medical Systems).
Vessel score was used to assess the extent of the atherosclerotic
disease in the coronary artery tree. Vessel score is based on the
number of diseased coronary arteries, where a coronary artery is
regarded as ‘diseased’ in the presence of  75% reduction in lumen
diameter.
18,19 Interobserver variability for vessel and stenosis score
was 3.1 and 4.2%, respectively.
Laboratory analysis
Peripheral blood samples were obtained from all patients after a 12 h
overnight fast, at the time of coronary angiography prior to heparin
infusion and to injection of any angiographic contrast material. Blood
specimens for rIL-8 and CEM analysis were collected in standard
vacutainer tubes containing citrate. A 3 mL aliquot of venous blood
collected in citrate plasma tubes was centrifuged at 1500 r.p.m. for
10 min at 48C; the plasma and buffy coat were carefully removed by
aspiration. Aliquots of plasma were stored at 2208C for IL-8 esti-
mation (pIL-8), and the remaining RBC were resuspended and
washed twice in 154 mM NaCl isotonic solution.
20
Isolation of erythrocyte membranes
Erythrocyte membranes were obtained according to the method pre-
viously reported
5 ensuring minimal haemoglobin contamination. The
procedure was carried out as follows: 1 mL of washed erythrocytes
solution was hypotonically lysed in 30 volumes of cold haemolysis
buffer (1 mM Tris–HCl, 1 mM EDTA, 10 mM NaCl, pH 7.2), mixed
by vortex and allowed to stand for 15 min. Membranes were separated
from the haemolysate (supernatant from haemolysed RBC) by cen-
trifugation at 15 000 r.p.m. for 15 min at 48C; this step was repeated
three times until a white/pale pink pellet containing haemoglobin-free
erythrocytes (ghosts) was obtained.
21
Erythrocyte ghosts were resuspended in 1 mL of PBS (phosphate
buffered saline) and stored at 2208C until further analysis. A
125 mL aliquot of membrane suspension was used to determine
D.N. Tziakas et al. 2714
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 membrane protein concentration by the method of Bradford using
bovine serum albumin as a standard.
22
Red blood cell membrane lipid extraction and
cholesterol estimation
Erythrocyte membrane samples (10 mg of protein), were extracted by
vigorous vortexing with 200 mL of chloroform-Triton X-100 (1%
Triton X-100 in pure chloroform). The extracts were centrifuged for
5 min in a microcentrifuge, at top speed. The organic phase (lower
phase) was collected and air dried at 508C to remove chloroform.
The remaining dried lipids (in Triton X-100) were then processed
for cholesterol determination. This extraction procedure was rec-
ommended as appropriate for the subsequent total cholesterol
content of RBC membrane lipid extracts measurements; using a colori-
metric assay kit by BioVision (Cholesterol/Cholesteryl Ester Quantiﬁ-
cation Kit – BioVision Research Products, Mountain View, CA, USA)
with a lower detection limit of 2 mg.
23 The assay kit is suitable for
measuring total cholesterol by prior incubation of all samples in the
presence of cholesterol esterase included in the reaction medium.
Intra- and inter-assay precision were both ,2%. A 6 point calibration
curve was prepared by diluting the Standard Solution provided in the
kit, the absorbance of each sample was measured against blank at
570 nm and the result was plotted against the calibration curve to
obtain the amount of total cholesterol. All the samples were measured
in duplicates and none of the duplicates had a coefﬁcient variation
(CV) .3%. We were able to measure the amount of cholesterol in
all the samples assayed. Results are expressed as micrograms of
membrane cholesterol (total) per milligram of membrane protein.
Plasma and red blood cell-bound
interleukin-8 estimation
IL-8 was measured in plasma obtained as described earlier. For
erythrocyte-bound IL-8, 1 mL of packed erythrocytes was washed
four times with 0.9% NaCl (200 g for 10 min) to eliminate the
remains of plasma, leucocytes, and platelets. The RBCs were adjusted
to the original whole blood volume, and were lysed by adding Triton
X-100 at a ﬁnal concentration of 0.1%.
24 The lysates were stored at
2208C. The removal of leucocytes as well as steady IL-8 RBC-bound
concentrations during the puriﬁcation procedure were shown by
measuring concentrations of myeloperoxidase (MPO)—a leucocyte
speciﬁc peroxidase—and IL-8 at each different step. In detail, at each
step after centrifugation, the buffy coat was removed and discarded
together with the top layer of sedimented RBCs at a height of
5 mm. Following, a sample of 100 mL (samples S#1, S#2, S#3,
S#4) was taken from the packed RBCs, solubilized with Triton
X-100 at a ﬁnal concentration of 0.1% and kept for analysis. At each
step during the puriﬁcation procedure declining MPO levels were
observed reaching non-detectable by the assay concentrations at
the ﬁnal separation steps (S#1 390+29 ng/mL, S#2 46+18 ng/mL,
S#3 and S#4 non-detectable concentrations). Furthermore, steady
IL-8 RBC-bound levels were shown at each separation step
(S#1 79+15 pg/mL, S#2 40+6 pg/mL, S#3 36+7 pg/mL and
S#4 35+4 pg/mL).
MPO concentrations were measured using an ELISA kit (Quantikine,
Human MPO, R&D Systems Inc., Minneapolis, MN, USA). IL-8 con-
centrations in plasma and erythrocyte lysates were measured with
an ELISA kit (AviBion Human IL-8 ELISA – Orgenium Laboratories,
Helsinki, Finland) with a lower detection limit of ,7 pg/mL. Plasma
samples were treated as recommended by the manufacturers,
whereas in the case of RBC lysates, 0.1% Triton X-100 was included
in the supplied sample dilution buffer used in the initial incubation
step, both with respect to blank, standards or samples alike.
Intra- and inter-assay precision was ,5.2 and ,6.4%, respectively.
Brieﬂy, an eight-point calibration curve was prepared by diluting the
Standard Solution provided in the kit, the absorbance of each
sample was measured against the blank at 450 nm. The result was
plotted against the calibration curve to obtain the amount of IL-8.
All the samples were measured in duplicates and none of the dupli-
cates had a CV .4%. Results are expressed as picograms of IL-8
per millilitre of plasma.
Statistical analysis
Continuous variables are presented as means+1 standard deviation
(SD) except in Figure 1 where they are presented as medians with
interquartile ranges and as percentages for categorical data. Compari-
sons between categorical variables were performed with the x
2 test or
Fisher’s exact test as appropriate. Unadjusted comparisons were made
by the Student’s unpaired t-test, in order to evaluate differences in
continuous variables between the two groups. Bonferroni’s correction
was used when appropriate. The planned sample size allowed a power
of 90% for the independent comparison (rIL-8 levels between ACS vs.
CSA) with a type 1 error probability of 0.05, assuming a mean differ-
ence equal to one half SD, on log-transformed data. Normality was
tested using the Kolmogorov–Smirnov test. CEM, CRP (C-reactive
protein), triglycerides, pIL-8 and rIL-8 levels were not normally distrib-
uted and were therefore logarithmically transformed as required to
approach normal distribution and to obtain equal variances. Analysis
of variance with covariates (ANCOVA) was used to evaluate differ-
ences in CEM, pIL-8 and rIL-8 levels between CSA and ACS after
adjustment for all the variables that were signiﬁcantly different
between the two groups. Similarly, ANCOVA method was used to
assess differences in the under investigation variables between ACS
vs. NCA and CSA vs. NCA group.
Figure 1 Interleukin concentration in erythrocyte membranes,
rIL-8, in patients with chronic stable angina (CSA), acute coronary
syndrome (ACS), and normal coronary artery (NCA) disease.
Box plots represent median, quartiles, and range values for
rIL-8. Data do not reﬂect logarithmic transformation or covariate
adjustment as assessed in the ANCOVA (analysis of variance with
covariates) model. P , 0.001 ACS vs. CSA, P , 0.001 ACS vs.
NCA, P ¼ 0.796 CSA vs. NCA.
IL-8 content of erythrocyte membrane and ACS 2715
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 Simple logistic regression analysis was used to assess univariate
associations among the three biochemistry indices (rIL-8, CEM, and
CRP) and CAD status (stable CAD vs. ACS). Odds ratios (OR) with
95% conﬁdence intervals (CI) were calculated. OR for standardized
log-transformed continuous variables reﬂect the relative risk for an
increase of 1 SD (of the transformed variable) in the measure.
25
Multiple logistic regression analysis was also used to assess the
independent adjusted relationship between these indices and CAD
status with independent variables being those that were signiﬁcantly
different between the two groups (ACS vs. CSA). The basic assump-
tion of linearity was assessed by plotting residuals vs. model predicted
values, for all dependent variables in each model.
The independent predictive ability of rIL-8 levels for CAD clinical
presentation was assessed using logistic regression models controlled
for CRP and CEM in a stepwise fashion (covariates þ rIL-8,
covariates þ rIL-8 þ CRP levels, covariates þrIL-8 þ CRP þ CEM
levels). The additive predictive ability of rIL-8 levels for CAD status
was tested using logistic regression models which additionally
controlled for CRP and CEM levels in an inverse stepwise
fashion (covariates þ CRP levels, covariates þ CRP þ CEM levels,
covariates þ CRP þ CEM þ rIL-8 levels); we compared the predictive
ability of these logistic regression models using the likelihood ratio-test
and the C-statistic.
In addition, the prognostic ability of rIL-8 in the subgroup of patients
with low and high CRP levels using its median value (5 mg/L) as cut-off
point (this level is considered to represent a clinically relevant concen-
tration associated with increased cardiovascular risk
26), was tested.
Correlation analysis between variables was carried out by means of
Spearman’s correlation coefﬁcient (r). Receiver-operating character-
istic (ROC) curves were calculated for rIL-8, CEM, and CRP levels.
A P-value ,0.05 was considered to indicate statistical signiﬁcance
with exception of pair-wise comparisons where Bonferroni’s correc-
tion was applied [P ¼ 0.05/n (n ¼ number of pair-wise comparisons)];
all tests were two-sided. The SPSS 11.0 statistical software package
(SPSS Inc., Chicago, IL, USA) was used for all calculations.
Results
Baseline characteristics
Baseline characteristics in patients with CSA, ACS, and those with
NCA are presented in Table 1. At the time of study entry, therapy
with b-blockers, statins, nitrates, calcium channel blockers, and
aspirin, was more common in CSA compared with other two
groups. Severity of CAD as determined by angiography was
similar between CSA and ACS patients.
No differences were observed in leucocyte (P ¼ 0.837), neutro-
phil (P ¼ 0.883), lymphocyte (P ¼ 0.662) count or neutrophils/
lymphocytes ratio (P ¼ 0.161) among the three groups.
Erythrocyte membrane and plasma
measurements
Content of rIL-8 was signiﬁcantly higher (P , 0.001) in ACS
(102.9+70. 1 pg/mL) compared with CSA (44.7+22.8 pg/mL)
(Figure 1). ANCOVA showed that rIL-8 remained signiﬁcantly
higher (P , 0.001) in ACS after adjustment for all the variables
that were signiﬁcantly different between ACS and CSA patients
(R
2 ¼ 0.314; for full model P , 0.001). Estimated covariate-
adjusted means with 95% CI for rIL-8 levels among the
two study groups assessed with the ANCOVA model were
83.2 pg/mL 95% CI 74.1–93.3 pg/mL for ACS and 39.8 pg/mL
95% CI 35.5–44.7 pg/mL for CSA.
Similarly, CEM levels were signiﬁcantly higher (P , 0.001) in
ACS (134.5+42.7 mg/mg) compared with CSA (77.2+
16.2 mg/mg). CEM levels remained different (P , 0.001) in an
ANCOVA model after adjustment for all the variables that were
different between CSA and ACS patients (R
2 ¼ 0.512, overall
P , 0.001).
As IL-8 load in erythrocyte membranes has not been extensively
assessed in the general population, we assessed rIL-8 levels in an
age and sex matched group of individuals with NCA as a mean
of comparison. Student’s t-test (P , 0.001) and ANCOVA (P ,
0.001) accounting for differences between the two groups,
showed that rIL-8 values were higher in ACS compared with
patients without angiographic CAD (48.2+25.4 pg/mL). In
contrast, rIL-8 was not signiﬁcantly different between patients
with NCA and those with CSA (t-test, P ¼ 0.796 and ANCOVA,
P ¼ 0.940).
Likewise, CEM levels were signiﬁcantly higher (t-test, P , 0.001
and ANCOVA, P , 0.001) in ACS compared with patients with
NCA (80.2+12.1 mg/mg); no difference was observed between
CSA and patients with NCA (t-test, P ¼ 0.197 and ANCOVA,
P ¼ 0.491).
No differences were noted in plasma IL-8 levels among CSA
(t-test, P ¼ 0.833 and ANCOVA, P ¼ 0.820), ACS (t-test, P ¼
0.053 and ANCOVA, P ¼ 0.528), and patients with NCA (51.3+
19.9 pg/mL). Likewise, plasma levels of IL-8 (pIL-8) were not differ-
ent among CSA (56.5+36.6 pg/mL) and ACS (64.8+33.2 pg/mL)
in both unadjusted (univariate Student’s t-test, P ¼ 0.057) or
adjusted (multivariable ANCOVA, P ¼ 0.280) comparisons.
Table 2 summarizes values of rIL-8, pIL-8, and CEM in the three
groups.
As it was expected, CRP levels were signiﬁcantly higher (P ,
0.001) in patients with ACS (31.3+28.2 mg/L) compared with
those with CSA (4.7+3.5 mg/L). Patients with NCA had lower
CRP levels (2.7+1.8 mg/L) compared with ACS (P , 0.001) and
CSA (P , 0.001) patients.
Prediction of coronary artery disease
instability
Table 3 summarizes results of simple logistic regression analysis for
each of the three major biochemical indices (CEM, rIL-8, CRP) that
could predict CAD instability. All the three parameters were pre-
dictive of ACS.
After adjustment for all the variables that were different
between the two groups (ACS, CSA) on univariate analysis (arter-
ial hypertension, current smoking, therapy with nitrates, statins,
b-blockers, calcium channel blockers, aspirin; and log triglyceride
levels), multiple logistic regression analysis showed that rIL-8,
CRP, and CEM levels continued to have an independent associ-
ation with ACS (Table 4). When the three biochemical indices
(rIL-8, CEM, and CRP) were included in the aforementioned
covariate-adjusted logistic regression model in a stepwise fashion
(covariates þ rIL-8 levels, covariates þ rIL-8 þ CRP levels,
covariates þ rIL-8 þ CRP þ CEM levels), rIL-8 continued to be a
signiﬁcant and an independent predictor of ACS (Table 4).
D.N. Tziakas et al. 2716
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Table 1 Demographic and clinical characteristics in patients studied
CSA
(n 5 120)
ACS
(n 5 118)
NCA
(n 5 36)
P-value
(CSA vs. NCA)
P-value
(ACS vs. NCA)
P-value
(CSA vs. ACS)
Men/women (n) 92/28 90/28 26/10 0.659 0.661 1
Age (years) 62 (9) 62 (10) 60 (7) 0.152 0.159 0.926
BMI 29 (4) 28 (4) 29 (6) 0.776 0.522 0.477
Erythrocyte count ( 10
6 per mL) 4.8 (0.4) 4.8 (0.4) 4.7 (0.4) 0.207 0.442 0.572
Haematocrit (%) 42.6 (3.6) 42 (3.2) 42.2 (4.9) 0.657 0.818 0.225
Haemoglobin (g/dL) 14.3 (1.3) 14.3 (1.4) 14 (1.9) 0.517 0.453 0.835
White blood cell count ( 10
3 per mL) 7.6 (1.7) 7.7 (1.6) 7.5 (1.8) 0.784 0.571 0.687
Neutrophils cell count ( 10
3 per mL) 4.4 (1.3) 4.5 (1.4) 4.4 (1) 0.877 0.809 0.628
Lymphocytes cell count ( 10
3 per mL) 2.5 (0.8) 2.6 (1) 2.4 (0.6) 0.681 0.323 0.526
Neutrophils/lymphocytes cell count ratio 1.9 (0.7) 2.2 (1.8) 1.8 (0.3) 0.839 0.076 0.100
History of ACS, n (%) 40 (33%) 32 (27%) – n/a n/a 0.325
History of coronary intervention
CABG, n (%) 8 (7%) 12 (10%) – 0.199 0.070 0.359
PCI, n (%) 8 (7%) 6 (5%) – 0.199 0.337 0.784
Co-morbidities
Stroke 2 (2%) 4 (3%) – 1 0.574 0.444
Peripheral vascular disease 6 (5%) 10 (8%) – 0.337 0.118 0.312
Risk factors
Diabetes mellitus, n (%) 48 (40%) 32 (27%) 8 (22%) 0.074 0.667 0.040
Arterial hypertension, n (%) 88 (73%) 68 (58%) 22 (61%) 0.211 0.847 0.014
a
Smoking, n (%) 42 (35%) 60 (51%) 12 (33%) 1 0.086 0.018
a
Family history of CAD, n (%) 26 (22%) 22 (19%) 6 (17%) 0.641 1 0.629
Medications
Nitrates, n (%) 48 (40%) 18 (15%) 10 (28%) 0.239 0.136 ,0.001
a
b-Blockers, n (%) 68 (57%) 34 (29%) 20 (56%) 1 0.005
a ,0.001
a
Calcium antagonists, n (%) 40 (33%) 20 (17%) 12 (33%) 1 0.058 0.004
a
ACE inhibitors, n (%) 44 (37%) 38 (32%) 4 (11%) 0.004
a 0.017
a 0.497
Angiotensin receptor blockers, n (%) 16 (13%) 20 (17%) 6 (17%) 0.593 1 0.473
Aspirin, n (%) 66 (55%) 28 (24%) 20 (56%) 1 0.001
a ,0.001
a
Clopidogrel, n (%) 30 (25%) 18 (15%) 8 (22%) 0.827 0.321 0.075
Statins, n (%) 54 (45%) 28 (24%) 22 (61%) 0.128 ,0.001
a 0.001
a
Fibrates, n (%) 6 (5%) 8 (7%) 2 (6%) 1 1 0.594
Ezetimibe, n (%) 6 (5%) 2 (2%) 4 (11%) 0.241 0.027 0.281
Omega-3 marine triglycerides, n (%) 2 (2%) 4(3%) 1 (3%) 0.670 0.856 0.444
Coronary arteriography
Non-signiﬁcant disease 10 (8%) 6 (5%) – n/a n/a 0.466
One-vessel disease 32 (27%) 36 (30%) –
Two-vessel disease 56 (47%) 48 (41%) –
Three-vessel disease 22 (18%) 28 (24%) –
LM disease 4 (3%) 4 (3%) – n/a n/a 1
Biochemistry
Creatinine (mg/dL) 0.98 (0.19) 1 (0.2) 0.86 (0.16) ,0.001
b ,0.001
b 0.087
Total cholesterol (mg/dL) 197 (37) 201 (43) 183 (47) 0.055 0.03 0.459
LDL cholesterol (mg/dL) 117 (32) 114 (39) 106 (39) 0.093 0.260 0.612
HDL cholesterol (mg/dL) 51 (12) 48 (10) 50 (12) 0.671 0.349 0.048
Triglycerides (mg/dL) 145 (59) 202 (175) 135 (81) 0.085 0.004
b 0.006
b
Continued
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 Finally, when the three under-investigation biochemical indices
(rIL-8, CRP, and CEM) were included in the covariate-adjusted
logistic regression model in an inverse stepwise fashion
(covariates þ CRP levels, covariates þ CRP þ CEM levels,
covariates þ CRP þ CEM þ rIL-8 levels) C-statistic and likelihood
ratio test showed that rIL-8 levels added signiﬁcantly to the predic-
tive ability compared with CRP and CEM levels (Table 5).
Receiver-operating characteristics curve
analysis
Consistent with the previous results, ROC analysis regarding
predictive accuracy for CAD status showed that for rIL-8, the
area under the curve was 0.826 (0.774–0.878); P , 0.001,
for CEM 0.921 (0.886–0.955); P , 0.001, and for CRP 0.831
(0.780–0.882); P , 0.001. Albeit without controlling for possible
cofounders, ROC analysis indicates that rIL-8 was a good marker
of CAD instability, comparable with CRP levels (Figure 2).
Correlation analysis
Correlation analysis in the entire patient population (n ¼ 238)
showed a signiﬁcant positive association between rIL-8 and CRP
plasma levels (r ¼ 0.294, P , 0.001) while no correlation was
found between plasma IL-8 and CRP levels (r ¼ 0.025, P ¼
0.706). Of interest, plasma IL-8 and rIL-8 levels were positively
correlated (r ¼ 0.283, P , 0.001). Furthermore, rIL-8 and CEM
were also positively associated (r ¼ 0.409, P , 0.001).
As it was expected,
5 no association was found between CEM
and: (i) serum total cholesterol concentration (r ¼ 0.047; P ¼
0.472), LDL (r ¼ 0.011; P ¼ 0.865), (ii) HDL-cholesterol levels
(r ¼ 20.043; P ¼ 0.512), and (iii) triglyceride levels (r ¼ 0.063;
P ¼ 0.337) when patients with ACS and CSA were included.
CEM levels were not correlated with number of diseased vessels
(r ¼ 20.007, P ¼ 0.881) or with stenosis score (r ¼ 0.031, P ¼
0.596). This was also the case for rIL-8 levels (for number of
diseased vessels: r ¼ 20.028, P ¼ 0.579, and for stenosis score:
r ¼ 0.017, P ¼ 0.746).
Subgroup analysis
The incidence of ACS in patients with CAD in relation to rIL-8 and
CRP is shown in Figure 3. It was observed that among CAD
patients with low CRP levels (n ¼ 126, CRP ,5 mg/L), rIL-8 was
signiﬁcantly associated with the presence of ACS (OR log rIL-8/
SD 18.6 95% CI 5.2–66.6, P , 0.001). Even among patients with
CAD with high CRP levels (n ¼ 112, CRP  5 mg/L), rIL-8 was
still predictive of ACS (OR logrIL-8/SD 4.7 95% CI 2.3–9.6, P ,
0.001). Furthermore, rIL-8 was a signiﬁcant predictor of CAD
instability across all quartiles of CRP, albeit stronger in the lower
spectrum (Figure 4).
The use of statins was associated with lower rIL-8 values (n ¼ 82,
60.4+53.4 pg/mL, P ¼ 0.001) compared with patients not receiv-
ing statins (n ¼ 156, 80.6+61.5 pg/mL). In view of the association
...............................................................................................................................................................................
Table 1 Continued
CSA
(n 5 120)
ACS
(n 5 118)
NCA
(n 5 36)
P-value
(CSA vs. NCA)
P-value
(ACS vs. NCA)
P-value
(CSA vs. ACS)
CRP (mg/L) 4.7 (3.5) 31.3 (28.2) 2.7 (1.8) ,0.001
b ,0.001
b ,0.001
b
Values are expressed as means+1 standard deviation for continuous variables, and as number of patients and% for categorical variables.
P , 0.02 was considered statistically signiﬁcant after applying Bonferroni’s correction.
ACE, angiotensin converting enzyme; ACS, acute coronary syndrome; BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CSA, chronic
stable angina; CRP, C-reactive protein; HDL, high density lipoprotein; LDL, low density lipoprotein; LM, left main; n/a, not applicable; NCA, normal coronary arteries; PCI,
percutaneous coronary intervention.
aFor x
2 test,
bfor Student’s unpaired t-test.
................................................................................
Table 2 Erythrocyte membrane and plasma
concentrations of interleukin-8 (rIL-8, pIL-8,
respectively) in chronic stable angina (CSA), acute
coronary syndrome (ACS) and patients with normal
coronary arteries (NCA)
CSA
(n 5 120)
ACS
(n 5 118)
NCA
(n 5 36)
rIL-8 (pg/mL) 44.7 (22.8) 102.9 (70.1) 48.2 (25.4)
pIL-8 (pg/mL) 56.5 (36.6) 64.8 (33.2) 51.3(19.9)
CEM (mg/mg) 77.2 (16.2) 134.5 (42.7) 80.2 (12.1)
Values are expressed as means+1 standard deviation for continuous variables.
For pair-wise comparisons P , 0.02 was considered statistically signiﬁcant after
applying Bonferroni’s correction.
................................................................................
Table 3 Prediction of coronary instability [univariable
logistic regression analysis for total cholesterol content
of erythrocyte membranes, interleukin-8 content of
erythrocyte membranes, C-reactive protein, in patients
with chronic stable angina and acute coronary
syndrome (n 5 238)]
Variable OR 95% CI P-value
Log rIL-8/SD 5.1 3.3–8.1 ,0.001
Log CEM/SD 23.7 10.2–54.8 ,0.001
Log CRP/SD 5.1 3.3–7.9 ,0.001
Odds ratios (ORs) reﬂect relative risk for a change in one standard deviation (SD).
SD (log rIL-8) ¼ 0.31, SD (log CEM) ¼ 0.16, SD (log CRP) ¼ 0.6.
CEM, total cholesterolcontent of erythrocyte membranes; CI, conﬁdence interval;
CRP, C-reactive protein; rIL-8, interleukin-8 content of erythrocyte membranes.
D.N. Tziakas et al. 2718
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 observed between statin use and rIL-8 levels we compared the pre-
dictive ability for ACS of rIL-8 in both patients with and without
statin treatment. In the subgroup of patients receiving statin treat-
ment, rIL-8 levels were predictive of ACS (OR log rIL-8/SD 11.1
95% CI 3.6–34.2, P , 0.001). Furthermore, rIL-8 levels were
also associated with ACS (OR log rIL-8/SD 3.9 95% CI 2.3–6.5,
P , 0.001) in the subgroup of patients not receiving statins.
The previous occurrence of an acute coronary event in some
patients in the CSA group may obscure the designation of CAD
clinical presentation as stable. We therefore, assessed the ability
................................................................................
................................................................................
................................................................................
Table 4 Multivariable logistic regression analysis in
patients with chronic stable angina and acute coronary
syndrome (ACS) (n 5 238) that could predict ACS
Variable OR 95% CI P-value
Model 1a (covariates þ log rIL-8/SD or þlog CEM/SD or þlog CRP/
SD)
Log rIL-8/SD 5 3–8.1 ,0.001
Log CEM/SD 25.4 10.1–64 ,0.001
Log CRP/SD 5.7 3.4–9.6 ,0.001
Model 2a (covariates þ log rIL-8/SD þ log CRP/SD)
Log rIL-8/SD 6 3.2–11.5 ,0.001
Log CRP/SD 6.6 3.4–12.7 ,0.001
Model 3a (covariates þ log rIL-8/SD þ log CRP/SD þ log CEM/SD)
Log rIL-8/SD 5.1 2.4–11 ,0.001
Log CRP/SD 4.9 2.1–11.3 ,0.001
Log CEM/SD 18.4 5.5–62 ,0.001
Odds ratios (ORs) reﬂect relative risk for a change in one standard deviation (SD);
SD (log rIL-8) ¼ 0.31, SD (log CEM) ¼ 0.16, SD (log CRP) ¼ 0.6.
Multivariable-adjusted analysis model 1a controlled for presence of arterial
hypertension, current smoking, use of nitrate, statins, b-blockers, calcium channel
blockers, aspirin and log triglyceride levels.
Multivariable-adjusted analysis model 2a controlled additionally for log CRP/SD.
Multivariable-adjusted analysis model 3a controlled additionally for log CRP/SD
and log CEM/SD.
CEM, total cholesterolcontent of erythrocyte membranes; CI, conﬁdence interval;
CRP, C-reactive protein; rIL-8, interleukin-8 content of erythrocyte membranes.
................................................................................
Table 5 Predictive ability of rIL-8 (interleukin-8
content of erythrocyte membranes) on the logistic
regression modelling
Model 1b Model 2b Model 3b
x
2 121.3 211.4 236.6
22 Log likelihood 208.6 118.5 93.3
P-value compared
with model 1
,0.001 ,0.001
C-statistic 0.876 0.958 0.971
Standard deviation (SD) (log rIL-8) ¼ 0.31, SD [log CEM (total cholesterol
content of erythrocyte membranes)] ¼ 0.16, SD [log CRP (C-reactive protein)] ¼
0.6.
Model 1b: covariates þ log CRP/SD.
Model 2b: covariates þ log CRP/SD þ log CEM/SD.
Model 3b: covariates þ log CRP/SD þ log CEM/SD þ log rIL-8/SD.
Covariates used in the logistic regression models: hypertension, current smoking,
nitrate, statin, b-blocker, calcium channel blocker, aspirin use, and log triglyceride
levels.
Figure 2 Receiver-operating characteristics (ROC) curve
analysis regarding predictive accuracy of acute coronary syn-
drome. The bold line represents ROC analysis for total choles-
terol content of erythrocyte membranes. The continuous line
represents ROC analysis for C-reactive protein levels The
dotted line represents ROC analysis for rIL-8 (interleukin-8
content of erythrocyte membranes) levels.
Figure 3 Number of patients with acute coronary syndrome in
a cross-tabulation of rIL-8 (interleukin-8 content of erythrocyte
membranes) by C-reactive protein (CRP) values. High rIL-8
levels:  59.5 pg/mL; low rIL-8 levels: ,59.5 pg/mL; high CRP
levels:  5 mg/L; low CRP levels: ,5 mg/L.
IL-8 content of erythrocyte membrane and ACS 2719
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 of rIL-8 to predict clinical instability in the subgroup of CSA
patients without a history of ACS (n ¼ 166). We found that
rIL-8 levels were associated with the occurrence of ACS (OR
log rIL-8/SD 6.9 95% CI 3.6–13.1, P , 0.001) in the subgroup of
patients without a previous history of ACS.
Discussion
The present study is the ﬁrst to report that IL-8 content in circu-
lating erythrocyte membranes is higher in ACS compared with
CSA patients. These results endorse and expand our previous ﬁnd-
ings
5 according to which high CEM levels were present in ACS
patients. In the present study, rIL-8 was a marker of ACS indepen-
dent of CRP and CEM concentrations.
27 Further, these ﬁndings
were independent of leucocyte and lymphocyte count.
28 It was
also found that rIL-8 content in the erythrocyte membranes was
associated with circulating levels of CRP.
That erythrocytes could play a role in plaque instability is bio-
logically plausible.
1 Recent studies have shown that neovasculari-
zation is important in the development of atherosclerotic
plaque and in its instability.
29–31 The newly formed vessels
may lead to the extravasation of erythrocytes within the athe-
rosclerotic plaque.
7 Red cells rich in cholesterol may contribute
to an abrupt volume expansion and to a change in the
lipid composition of the plaque, thus the lipid core becomes
rich in free cholesterol,
1,2,5 an important determinant of plaque
vulnerability.
4,6,32,33
Further, it is quite plausible that extravasated erythrocytes may
initiate and propagate an inﬂammatory cascade
2,4,7,8 within the
atherosclerotic plaque, which may play a pathogenic role in CAD
progression and plaque rupture.
9,10,34,35
This inﬂammation cascade may be promoted by receptors
present on erythrocyte membranes, which bind to a wide array
of chemokines including IL-8 and monocyte chemotactic
peptide-1.
4,12,36,37
IL-8 is a C–X–C chemokine that has the potential of modulat-
ing atherosclerosis progression.
11 A number of studies have shown
that IL-8 is present in human atherosclerotic plaques in patients
with UA.
38–44 IL-8 has been shown to be a potent chemotactic
factor for T-lymphocytes
45 and monocytes.
46 In addition to its
chemoattractant properties, it also possesses other plaque destabi-
lizing effects. IL-8 contributes to smooth muscle cell migration and
proliferation,
47 a possible source of matrix metalloproteinases,
48
and additionally down-regulates the action of inhibitors of
metalloproteinases.
49 Further, IL-8 is a signal for angiogenesis,
43 an
important mechanism of atherosclerotic plaque instability.
29–31
Finally, it has been suggested that IL-8 is a key participant in the
cross talk between coagulation activation and cytokine cascades.
50
C–X–C chemokines may have also atheroprotective effects.
Keratinocyte-derived chemokine (KC) the mouse ortholog
of human growth-related oncogene (GRO-a)—a C–X–C
chemokine—has been shown to exert a protective effect on
plaque formation after endothelial denudation (endothelial
wound injury) presumably by accelerated re-endothelialization.
This implies that KC may exert a protective role in neointima
formation especially in the setting of restenosis by accelerating
endothelial recovery.
51
Our results are in agreement with that of de Winter et al.
24 who
have shown that IL-8 is mainly bound to erythrocytes in patients
suffering from an acute MI and their levels of rIL-8 were signiﬁ-
cantly higher compared with those in healthy controls. In contrast,
other studies reported that plasma levels of IL-8 were signiﬁcantly
higher in ACS compared with CSA.
52,53 An explanation for this
disparity may be the timing of blood sampling in the ACS patient
group. In the aforementioned studies
52,53 blood samples were
obtained during the acute phase of the event, whereas in our
study blood was obtained 15 days after the acute event. It is
known that circulating levels of IL-8 in ACS return to normal
values within a few days from the onset of symptoms.
24 Thus,
pIL-8 and rIL-8 levels are changing constantly for a few days after
the acute event and steady-state condition is reached several
days after the acute ischaemic syndrome. The present study was
designed to assess the diagnostic ability of the aforementioned
markers at steady-state condition.
It should be emphasized that the present study demonstrated
that erythrocyte membranes IL-8 level is increased in patients
with ACS compared with CSA. At present, there is not sufﬁcient
information to suggest that rIL-8 is involved in the pathogenetic
mechanisms related to unstable atherosclerotic plaque. Thus, the
concept that erythrocytes—entrapped within the atherosclerotic
plaque—propagating an inﬂammatory response and interfering
with plaque instability at present is speculative.
54 This, however,
does not detract from the fact that rIL-8 is at least a marker of
CAD instability.
In summary, this study showed that IL-8 contained in erythro-
cyte membranes is associated with the presence of ACS. It is
quite plausible that intraplaque haemorrhage and consequently
extravasated erythrocytes may contribute to plaque instability via
Figure 4 Predictive ability of rIL-8 (interleukin-8 content of
erythrocyte membranes) in relation to C-reactive protein
(CRP) quartiles. Range of CRP quartiles and number of patients
with chronic stable angina (CSA) and acute coronary syndrome
(ACS) within each quartile. Quartile 1:  2 mg/L, 62 patients,
52 with CSA, 12 with ACS; quartile 2: .2 and  5 mg/L, 64
patients, 44 with CSA, 20 with ACS; quartile 3: .5 and
 19 mg/L, 52 patients, 18 with CSA, 34 with ACS; quartile 4:
.19 mg/L, 60 patients, 8 with ACS, 52 with CSA.
D.N. Tziakas et al. 2720
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 inﬂammatory mechanisms, in addition to the enlargement of the
necrotic lipid core. Thus—as suggested in previous studies from
our group—erythrocytes may play an active role in the athero-
sclerotic plaque progression and in plaque instability.
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